Bristol-Myers Squibb Company (BMY)

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.

The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-11-01.

Filed figures from SEC EDGAR, in the reporting currency.

• BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress — TradingView Newstradingview.com
• BMY Stock Catalyst Calendar: Earnings Dates, Events & Key Triggers | Catacalcatacal.com
• Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet - 24/7 Wall St.247wallst.com
• What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)?finance.yahoo.com
• Bristol Myers Squibb (BMY): The Best Quarter Before the Cliff | Q2 2026youtube.com

Headlines link to their source. Sperio does not republish article text.